AMICUS THERAPEUTICS, INC. — Director's Dealing 2015

Mar 25, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2015-03-20

Reporting Person: Valenzano Ken (VP, Pharmacology & Biology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-03-20	Common stock	M	6043	$11.6755	Acquired	57751	Direct
2015-03-20	Common stock	S	6043	$11.6755	Disposed	51708	Direct
2015-03-20	Common stock	S	1708	$12.11	Disposed	50000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-03-20	Stock Options (right to buy)	$0.6375	M	543	Disposed	2015-06-09	Common Stock (543)	Direct
2015-03-20	Stock Options (right to buy)	$5.325	M	2000	Disposed	2015-10-20	Common Stock (2000)	Direct
2015-03-20	Stock Options (right to buy)	$2.52	M	3500	Disposed	2023-06-18	Common Stock (3500)	Direct

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2014.

F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.20 to $12.11. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.20 to $12.11. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.